20:11 , Mar 1, 2019 |  BC Week In Review  |  Financial News

Blackstone, Novartis spin out cardiovascular newco Anthos

Leading its first deal since acquiring Clarus Ventures, Blackstone has partnered with Novartis AG (NYSE:NVS; SIX:NOVN) to launch Anthos Therapeutics Inc. (Cambridge, Mass.) with $250 million and Novartis antithrombotic MAA868. In exchange for the compound,...
19:38 , Feb 27, 2019 |  BC Extra  |  Company News

Blackstone, Novartis spin out cardiovascular newco Anthos

Leading its first deal since acquiring Clarus Ventures, Blackstone has partnered with Novartis AG (NYSE:NVS; SIX:NOVN) to launch Anthos Therapeutics Inc. (Cambridge, Mass.) with $250 million and Novartis antithrombotic MAA868. In exchange for the compound,...
17:22 , Apr 20, 2018 |  BC Week In Review  |  Company News

BMS, JNJ in deal for Factor XIa inhibitor

Bristol-Myers Squibb Co. (NYSE:BMY) and the Janssen Pharmaceuticals Inc. unit of Johnson & Johnson (NYSE:JNJ) partnered to develop and commercialize Factor XIa inhibitors, including BMS-986177. BMS will receive an undisclosed upfront payment and is eligible...
20:26 , Apr 16, 2018 |  BC Extra  |  Company News

BMS, JNJ in deal for Factor XIa inhibitor

Bristol-Myers Squibb Co. (NYSE:BMY) and the Janssen Pharmaceuticals Inc. unit of Johnson & Johnson (NYSE:JNJ) partnered to develop and commercialize Factor XIa inhibitors, including BMS-986177. BMS will receive an undisclosed upfront payment and is eligible...
23:48 , Nov 30, 2017 |  BC Week In Review  |  Clinical News

eXIthera reports Phase I data for thrombosis candidate

eXIthera Pharmaceuticals Inc. (Westborough, Mass.) reported data from a Phase I trial in 60 healthy volunteers showing that thrombosis candidate EP-7041 was well tolerated with no serious adverse events reported. The company said the compound's...
22:59 , Aug 28, 2017 |  BC Extra  |  Clinical News

Xarelto lowers CV risk, ups major bleeds in artery disease

The Janssen Research & Development LLC unit of Johnson & Johnson (NYSE:JNJ) released full data from the Phase III COMPASS trial showing that twice-daily 2.5 mg oral Xarelto rivaroxaban plus once-daily 100 mg aspirin reduced...
18:34 , Mar 8, 2017 |  BC Innovations  |  Translation in Brief

Up to eleven

Factor XI inhibitors may not only have safety advantages over more established anticoagulants, but could come with blood pressure-lowering benefits as well. A Science Translational Medicine study from Ionis Pharmaceuticals Inc. (NASDAQ:IONS) and Johannes Gutenberg...
07:00 , Sep 29, 2016 |  BC Innovations  |  Product R&D

Safety Factor

Although the advent of Factor Xa inhibitors improved quality of life for many thrombosis patients, the compounds' bleeding risk prevents use in patient populations with certain co-morbidities, and has prompted a handful of companies to...
07:00 , Sep 15, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Factor XIa

Cardiovascular disease INDICATION: Thrombosis In vitro, mouse and rabbit studies suggest an anti- Factor XIa mAb could help treat thrombosis. Screening of an antibody library and mutagenesis of hits identified a mAb that inhibited human...
08:00 , Jan 8, 2015 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Factor XIa

Cardiovascular disease INDICATION: Thrombosis In vitro and rabbit studies have identified a phenylimidazole-based factor XIa inhibitor that could help treat thromboembolic disorders. In vitro, the lead compound reversibly inhibited factor XIa at subnanomolar Ki values....